Glucagon receptor antagonists
AssigneeEli Lilly and Company
InventorsAndrew Ihor KORYTKO, Rohn Lee MILLICAN, JR.
Life of this patent
Estimating the term…
Abstract
The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and their use in the treatment or prevention of type 2 diabetes (NIDDM) and related disorders in mammalian species.
Claims8
1-15. (canceled)
A humanized monoclonal antibody that inhibits binding of glucagon to a glucagon receptor, wherein the antibody comprises a light chain and a heavy chain, wherein
- (i) the light chain comprises
- a CDRL1:
- S X S S S V S Y X1 H,
- SEQ ID NO:
- 53
- a CDRL2:
- T T S X2 L A H,
- SEQ ID NO:
- 54
- a CDRL3:
- X3 X4 R S T X5 P P T;
- SEQ ID NO:
- 55
- and
- (ii) the heavy chain comprises
- SEQ ID NO:
- 56
- a CDRH1:
- G D D I T S G Y X6 X7,
- SEQ ID NO:
- 57
- a CDRH2:
- Y I S Y S G S T X8 Y X9 P S L K S,
- SEQ ID NO:
- 58
- a CDRH3:
- P P X10 Y Y G F G P Y A X11 D Y,
- wherein:
- X is Y or A;
- X1 is M or I;
- X2 is N or Y;
- X3 is Q or L;
- X4 is Q or W;
- X5 is L or I;
- X6 is W or H;
- X7 is N, D or E;
- X8 is Y, Q, S or V;
- X9 is N, S or I;
- X10 is G or A;
- X11 is M or L.
Dependencies are inferred from the claim text.